We aim at developing and evaluating new diagnostic, prognostic and therapeutic approaches for paediatric leukaemias using high-end multi-colour flow cytometry.
Prof. Thomas Lion, MD, PhD
Our group primarily focuses on the improvement of treatment outcomes, particularly in transplant recipients and patients with life-threatening infections, by developing and implementing new diagnostic technologies.
Studies & Statistics for Integrated Research and Projects
Prof. Ruth Ladenstein, MD, MBA, cPM
Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management.
Pathobiology of LCH
Caroline Hutter MD, PhD
The goal of our laboratory is to better understand the pathobiology of Langerhans Cell Histiocytosis (LCH) in order to develop new treatment approaches to the disease.
Innovative cancer models
Martin Distel, PhD
Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level. In addition, zebrafish disease models are applied in small compound screens to identify therapeutic compounds.